CARDIOVASCULAR JOURNAL OF AFRICA • Volume 34, No 3, July/August 2023 AFRICA 139 2013; 309(9): 896–908. 11. Li X, Fan X, Li S, Sun W, Shivkumar K, Zhao S, et al. A novel risk stratification score for sudden cardiac death prediction in middle-aged, nonischemic dilated cardiomyopathy patients: the ESTIMATED score. Can J Cardiol 2020; 36(7): 1121–1129. 12. Luo N, O’Connor CM, Chiswell K, Anstrom KJ, Newby LK, Mentz RJ. Survival in patients with nonischemic cardiomyopathy with preserved vs reduced ejection fraction. CJC Open 2021; 3(11): 1333–1340. 13. Dokainish H, Rajaram M, Prabhakaran D, Afzal R, Orlandini A, Staszewsky L, et al. Incremental value of left ventricular systolic and diastolic function to determine outcome in patients with acute ST-segment elevation myocardial infarction: the echocardiographic substudy of the OASIS-6 trial. Echocardiography 2014; 31(5): 569–578. 14. Ge Y, Antiochos P, Qamar I, Seno A, Steigner ML, Aghayev A, et al. Diagnostic impact and prognostic value of cardiac MRI in patients with ventricular arrhythmias. J Am Coll Cardiol 2020; 75(11 Supplement 1): 3665. 15. Flett AS, Hasleton J, Cook C, Hausenloy D, Quarta G, Ariti C, et al. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. J Am Coll Cardiol Cardiovasc Imaging 2011; 4(2): 150–156. 16. Gao P, Yee R, Gula L, Krahn AD, Skanes A, Leong-Sit P, et al. Prediction of arrhythmic events in ischemic and dilated cardiomyopathy patients referred for implantable cardiac defibrillator: evaluation of multiple scar quantification measures for late gadolinium enhancement magnetic resonance imaging. Circ Cardiovasc Imaging 2012; 5(4): 448–456. Several low-dose drugs better for BP than one pill: Australian meta-analysis Researchers have found that taking three or four medications at lower doses, rather than just a single pill, may help people lower their blood pressure without increasing the risk of most negative side effects. To estimate how much benefit this kind of low-dose combination therapy offers for controlling blood pressure, a team, led by the University of New South Wales, Australia, reviewed seven previous randomised clinical trials, and also combined the results of these studies, using the statistical method known as a meta-analysis, reports Healthline. Their findings, published in Journal of the American Medical Association, Cardiology, suggest that combining low doses of three or four blood pressure-lowering medications is safe and effective as an initial treatment strategy for high blood pressure. Previously, three-drug combinations had been recommended only if people have difficulty keeping their blood pressure under control with two drugs. The seven randomised clinical trials compared low-dose combinations of three or four blood pressure-lowering drugs to treatment with a single drug, usual care, or an inactive placebo. Researchers defined low doses as half or less than half the standard dose. The clinical trials included 1 918 patients. In five of the trials, participants were followed for four to 12 weeks, and for six to 12 months in the other two trials. People treated with low-dose drug combinations saw their systolic blood pressure decrease on average by 16 to 28 mmHg over four to 12 weeks, the analysis showed. In contrast, systolic blood pressure decreased 12 to 18 mm Hg on average in the group taking one drug or receiving usual care. At six and 12 months, people receiving low-dose combination therapy continued to have greater reductions in their blood pressure compared with the one-drug or usualcare groups. Low-dose combination therapy also lowered blood pressure more than placebo. In addition, a greater percentage of people receiving low-dose combination therapy lowered their blood pressure below 140/90 mmHg, compared with those receiving one drug or usual care. This was true during the short- and longterm follow ups. According to the American Heart Association, hypertension stage two is when the blood pressure is consistently at or above 140/90 mmHg. Two-thirds of people in the clinical trials were able to control their blood pressure with low-dose combination therapy, the researchers found. However, that means that one-third would ‘require treatment intensification to achieve better control rates,’ they wrote. Overall, there was a low risk of adverse effects with low-dose combination therapy, although people taking three or four medications were more likely to experience dizziness than those treated with one drug or usual care. One limitation of the analysis is that some of the clinical trials included people who were taking blood pressurelowering medications at the start of the trial, so low-dose combination therapy was not their initial treatment. However, the authors of the study found that the results were similar when they compared people who had already been taking medications to those who started on the low-dose combination therapy. Another limitation was that the analysis included only a few clinical trials, with just two trials following patients for six to 12 months, meaning the researchers might not be able to clearly see if people on the low-dose combination therapy had fewer or more side effects than the other groups. Dr Michael Broukhim, an interventional cardiologist at Providence Saint John’s Health Centre in Santa Monica, said larger studies would be needed to clearly assess the adverse effects of low-dose combination therapy. Ideally, he would like to see a larger randomised clinical trial that compares low-dose combination therapy to taking a single pill, focused on people with high blood pressure but no related health conditions. The study also shows patients tolerate low doses of multiple medications, an approach that may work better than increasing the dose of a single medication to achieve blood pressure control. With many medications, upping the dosage increases the risk of negative side effects. continued on page 148…
RkJQdWJsaXNoZXIy NDIzNzc=